NSE · VIYASH
Viyash Scientific Limited
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹354 Cr with net profit ₹21 Cr — a 5.91% net margin, versus 5.12% the period before.
Shareholding
As of 2026-09-30
- Promoter49.24%
- Public39.86%
- FII2.6%
- DII8.3%
1,42,732 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 1.67× from low to high.
Risk flags
Derived from disclosed data
- Promoter holding fell 12.06 percentage points to 49.24% in the latest disclosure.
Peer comparison
Pharmaceuticals - Indian - Bulk Drugs & Formln · ranked #28 of 102 by market cap · medians across 49 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | ₹4,23,387 Cr | 33.51 | 5.07 | 13.74% | 20.29% |
| Zydus Lifesciences Ltd. | ₹1,16,927 Cr | 23.95 | 4.31 | 18.59% | 16.09% |
| Laurus Labs Limited | ₹1,14,654 Cr | 104.84 | 21.63 | 16.77% | 15.04% |
| Cipla Ltd. | ₹1,10,194 Cr | 30.79 | 3.2 | 11.27% | 12.06% |
| Dr Reddys Laboratories Ltd. | ₹1,10,178 Cr | 39.36 | 2.84 | 7.21% | 8.49% |
| Mankind Pharma Limited | ₹1,03,951 Cr | 48.73 | 6.38 | 12.76% | 14.58% |
| Aurobindo Pharma Ltd. | ₹93,769 Cr | 24.8 | 2.47 | 9.25% | 10.7% |
| Lupin Limited | ₹89,648 Cr | 15.05 | 3.99 | 23.76% | 18.72% |
| Glenmark Pharmaceuticals Ltd. | ₹63,684 Cr | 20.4 | 6.06 | 28.08% | 10.22% |
| Alkem Laboratories Ltd. | ₹60,775 Cr | 26.67 | 4.4 | 16.66% | 14.31% |
| Viyash Scientific Limited(this company) | ₹9,547 Cr | 42.54 | 3.39 | 7.07% | 5.91% |
AI analysis
AI-generated · google/gemini-2.5-flashViyash Scientific Limited (VIYASH) is listed on the Indian markets with a market capitalization of Rs 11558 Cr. The company reported revenue of Rs 1566.06 Cr with a revenue growth of 13.3%. The profit margin stood at 5.2%.
Positives
- +Revenue grew by 13.3% to Rs 1566.06 Cr.
- +The debt-to-equity ratio is low at 0.21.
- +Promoter shareholding is substantial at 61.3082% as of June 30, 2026.
- +No promoter shares are pledged.
Negatives
- −The profit margin is 5.2%.
- −Return on equity (ROE) is 7.07%.
- −Net profit in Dec 2025 was negative at -Rs 0.08 Cr.
- −The company has not declared any dividend (dividend yield 0).
Financial performance
Viyash Scientific Limited reported an annual revenue of Rs 1566.06 Cr with a revenue growth of 13.3%. Quarterly revenue was Rs 919.96 Cr in Mar 2026, with net profit of Rs 52.11 Cr. The earnings per share (EPS) for Mar 2025 was Rs 0.85.
Profitability & returns
The company's profit margin is 5.2%. Return on equity (ROE) is 7.07% and return on capital employed (ROCE) is 13.0083%. The diluted EPS is Rs 4.64.
Balance sheet
The company has a debt-to-equity ratio of 0.21. No dividend yield was reported. The book value per share is Rs 64.51.
Ownership & pledges
As of June 30, 2026, the promoter holding in Viyash Scientific Limited was 61.3082%, with no shares pledged. Public shareholding was 30.4366%, FIIs held 4.502%, and DIIs held 3.7532%. Institutions held 8.2552%.
Data as of — price: 2026-10-27 · financials: Jun 26 · shareholding: Sep 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.